The prevalence of steatohepatitis in chronic hepatitis B patients and its impact on disease severity and treatment response

Liver International

Volumn 37, Issue 4, 2017, Pages 542-551

  Charatcharoenwitthaya, Phunchai ^a   Pongpaibul, Ananya ^a   Kaosombatwattana, Uayporn ^a   Bhanthumkomol, Patommatat ^a   Bandidniyamanon, Wimolrak ^a   Pausawasdi, Nonthalee ^a   Tanwandee, Tawesak ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

antiviral therapy; hepatitis B; liver fibrosis; metabolic syndrome; Steatohepatitis

Indexed keywords

AMINOTRANSFERASE; ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANTHROPOMETRIC PARAMETERS; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS B; CLINICAL EVALUATION; DISEASE ASSOCIATION; DISEASE SEVERITY; FATTY LIVER; FEMALE; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTRIGLYCERIDEMIA; IMMUNOADSORPTION; LABORATORY TEST; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MONOTHERAPY; OBESITY; PREVALENCE; RISK FACTOR; TREATMENT RESPONSE; VIREMIA; BLOOD; COMPLICATION; HEPACIVIRUS; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; STATISTICAL MODEL; SUSTAINED VIROLOGIC RESPONSE; THAILAND;

ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; FATTY LIVER; FEMALE; HEPACIVIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME; MIDDLE AGED; OBESITY; PROSPECTIVE STUDIES; RISK FACTORS; SUSTAINED VIROLOGIC RESPONSE; THAILAND;

EID: 84997335811     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13271     Document Type: Article

References (27)

1. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28:155–161.
2. Kim KH, Shin HJ, Kim K, et al. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPAR gamma. Gastroenterology. 2007;132:1955–1967.
3. Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol. 2011;26:1361–1367.
4. Thomopoulos KC, Arvaniti V, Tsamantas AC, et al. Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis. Eur J Gastroenterol Hepatol. 2006;18:233–237.
5. Zheng RD, Xu CR, Jiang L, Dou AX, Zhou K, Lu LG. Predictors of hepatic steatosis in HBeAg-negative chronic hepatitis B patients and their diagnostic values in hepatic fibrosis. Int J Med Sci. 2010;7:272–277.
6. Bondini S, Kallman J, Wheeler A, et al. Impact of non-alcoholic fatty liver disease on chronic hepatitis B. Liver Int. 2007;27:607–611.
7. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389–397.
8. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implication for policy and intervention strategies. Lancet. 2004;363:157–163.
9. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–1645.
10. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostatic model assessment: insulin resistance and beta-cell function from fasting glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419.
11. Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and Iron Overload Screening (HEIRS) Study Research Investigators. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med. 2005;352:1769–1778.
12. Kleiner DE, Brunt EM, Van Natta M, et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321.
13. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–2474.
14. The METAVIR cooperative group. Inter- and intra-observer variation in the assessment of liver biopsy of chronic hepatitis C. Hepatology. 1994;20:15–20.
15. Mani H, Kleiner DE. Liver biopsy findings in chronic hepatitis B. Hepatology. 2009;49:S61–S71.
16. Pagadala MR, McCullough AJ. The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis. Clin Liver Dis. 2012;16:487–504.
17. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012;142:711–725.
18. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468–475.
19. Bugianesi E, Manzini P, D'Antico S, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology. 2004;39:179–187.
20. Khalili M, Lombardero M, Chung RT, et al. Diabetes and prediabetes in patients with hepatitis B residing in North America. Hepatology. 2015;62:1364–1374.
21. Yoon H, Lee JG, Yoo JH, et al. Effects of metabolic syndrome on fibrosis in chronic viral hepatitis. Gut Liv. 2013;7:469–474.
22. Wong GL, Chan HL, Yu Z, et al. Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B-a prospective cohort study with paired transient elastography examinations. Aliment Pharmacol Ther. 2014;39:883–893.
23. Matthew Morris E, Fletcher JA, Thyfault JP, Rector RS. The role of angiotensin II in nonalcoholic steatohepatitis. Mol Cell Endocrinol 2013;378:29–40.
24. Ibañez P, Solis N, Pizarro M, et al. Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis. J Gastroenterol Hepatol. 2007;22:846–851.
25. Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology. 2004;40:1222–1225.
26. Mangia A, Ripoli M. Insulin resistance, steatosis and hepatitis C virus. Hepatol Int. 2013;7(Suppl 2):782–789.
27. Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014;28:637–653.